Natera Inc. ((NTRA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The FIND-CRC study, officially titled ‘Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population,’ aims to assess the clinical performance of Natera’s CRC Screening Test. The study focuses on collecting samples and data from individuals at average risk of developing colorectal cancer, providing valuable insights into the test’s effectiveness.
The intervention being tested is the Natera Colorectal Cancer Screening Test, designed to detect colorectal cancer in its early stages among average-risk individuals. This non-invasive test uses whole blood samples to identify potential cancer markers.
The study is observational, following a cohort model with a prospective time perspective. Participants are individuals aged 40 or older who plan to undergo asymptomatic screening colonoscopy. The primary purpose is to gather data on the test’s performance without any masking or allocation.
The study began on June 13, 2025, with the latest update submitted on June 27, 2025. These dates mark the start of participant recruitment and the most recent information available, respectively, highlighting the study’s active status.
This update could positively influence Natera Inc.’s stock performance by showcasing their commitment to advancing cancer screening technologies. As the study progresses, investor sentiment may be bolstered by potential breakthroughs in the early detection of colorectal cancer, setting Natera apart in a competitive market.
The FIND-CRC study is ongoing, with further details accessible on the ClinicalTrials portal.